Merck & Co., Inc.

NYSE: MRK·Rahway, New Jersey·

Price
$144.46
Base IV
$114.37

Valuation snapshot

Above base case

At $144.46, the price sits between our base case ($114.37) and bull case ($170.21).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$114.37
79% of the price · range $68.64–$170.21
Price vs base case
26% above
$144.46 against $114.37
Base casevalued by DCF
Price vs base
Priceclose 11‑16

The price has fallen 3.9% since this valuation was struck on 2026-11-05, so some of the gap opened up after these figures were set.

Whisker on the base case runs bear $68.64 to bull $170.21. Values per share.

Price against each value

Bear case
$68.64
Price 110% above
No growth
…
—
Base case
$114.37
Price 26% above
Researched bygemini-3.8-flash-medium
Valuation Nov 5, 2026 · Price as of Nov 16, 2026How we got here

What does Merck & do?

Merck develops medicines and vaccines that help doctors treat cancer, prevent infections like HPV, and manage other serious diseases, and offers vaccines and parasite treatments that keep livestock and pets healthy.

It brought in $67.4B of sales in the 12 months to Sep 2026.

Industry
Healthcare
Based in
Rahway, New Jersey
Trades on
NYSE as MRK

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 4¢ was left as profit after every cost, interest and tax. The biggest cost is research and development, 46¢ of every dollar.

  • Making what it sells28¢
  • Research and development46¢
  • Sales, marketing and admin17¢
  • Everything else, including interest2¢
  • Tax3¢
  • Left as profit4¢
Totals of the four quarters to Sep 2026, from the company's own filings.

Who pays Merck &, and for what?

Merck develops, makes and sells prescription medicines and vaccines for people, plus medicines, vaccines and tracking tags for farm animals and pets. Most of its money comes from medicines protected by patents. Its cancer drug Keytruda brought in about half of its $65.0 billion in sales in 2025.

Drug wholesalers, pharmacies, hospitals, doctors, insurers and government agencies pay for its human medicines and vaccines; veterinarians, distributors, farmers and pet owners pay for its animal products.

  • Keytruda / Keytruda Qlex

    49%

    A cancer medicine that helps the immune system attack tumors. It is approved for many types of cancer and can be given by IV drip or, as Keytruda Qlex, by injection under the skin.

  • Animal Health

    10%

    Medicines, vaccines and digital tracking products for livestock, fish and pets, including the Bravecto flea and tick line. Sales were $6.35 billion in 2025.

  • Gardasil / Gardasil 9

    8%

    Vaccines that help prevent cancers and diseases caused by HPV. Sales fell from $8.6 billion in 2024 to $5.2 billion in 2025, mainly because of lower sales in China.

  • Januvia / Janumet

    4%

    Pills for type 2 diabetes. They lose US patent protection in 2026, and the US government has set a price for them under Medicare.

  • Lynparza and Lenvima partnership revenue

    4%

    Merck's share of the profits from two cancer drugs it sells with partners: Lynparza with AstraZeneca and Lenvima with Eisai.

  • Winrevair

    2%

    A newer medicine for pulmonary arterial hypertension, a form of high blood pressure in the lungs. Sales grew from $419 million in 2024 to $1.44 billion in 2025.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • West Point Site — West Point, United States. Merck identifies West Point as its largest U.S. manufacturing facility, supporting the research, manufacture and testing of pharmaceuticals and vaccines.
  • Merck Wilmington Biotech — Wilmington, United States. This $1 billion biologics center is intended to become Merck's U.S. manufacturing home for KEYTRUDA and support commercial production of next-generation biologics, including antibody-drug conjugates.
  • Durham Vaccine Manufacturing Site — Durham, United States. Merck's Durham campus includes a newly opened $1 billion, 225,000-square-foot facility dedicated to expanding vaccine manufacturing capacity.
  • Elkton Pharmaceutical Manufacturing Center — Elkton, United States. A $3 billion, 400,000-square-foot expansion will add active-pharmaceutical-ingredient and finished-drug capacity for small-molecule products at Merck's longstanding Elkton site.
  • Singapore Operations — Singapore, Singapore. Merck's Singapore footprint combines its Asia-Pacific headquarters with translational-medicine research, manufacturing facilities and a regional IT hub.
See them on the globe

Merck & Co., Inc. Form 10-K for fiscal year 2025

How is the business doing?

Sales grew from $43.3B in 2020 to $65B in 2025, about 8% a year.

After paying for its upkeep and new investment, it had $14.7B of cash to spare in the 12 months to Sep 2026.

Sales$65B
20092025
Free cash flow$12.4B
20092025
Each bar is one fiscal year (2009–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Merck says it exists to use advanced science to discover medicines and vaccines that save and improve lives around the world.

“help save and improve lives around the world”

Merck Canada company overview

What management says it is working on now:

  • Building new medicines in its research pipeline

    Merck says it follows a science-led strategy. It had about 80 late-stage (Phase 3) studies underway and started 21 new ones in 2025, covering cancer, heart and lung disease, infections, immune diseases and eye disease.

    Merck & Co., Inc. Form 10-K for fiscal year 2025
  • Buying and licensing outside science

    Merck adds to its own research through deals. In 2025 it bought Verona Pharma, which makes the lung medicine Ohtuvayre, and agreed to buy Cidara for a flu-prevention drug. It also licensed experimental medicines from Hengrui Pharma and Dr. Falk Pharma.

    Merck & Co., Inc. Form 10-K for fiscal year 2025
  • Launching new products

    Merck is rolling out Keytruda Qlex (a version given as an injection under the skin), wider use of Winrevair, the adult pneumonia vaccine Capvaxive and Enflonsia, which protects infants from RSV.

    Merck & Co., Inc. Form 10-K for fiscal year 2025
  • Widening its cancer business beyond Keytruda

    Merck is building its cancer research around three areas: drugs that use the immune system, drugs aimed at specific gene changes, and drugs that deliver treatment straight to tumor cells.

    Merck & Co., Inc. Form 10-K for fiscal year 2025
  • Paying shareholders and investing in US manufacturing

    Merck raised its quarterly dividend to $0.85 per share and returned $13.3 billion to shareholders in 2025. It also agreed with the US government to delay certain tariffs for three years while it invests in making more of its products in the US.

    Merck & Co., Inc. Form 10-K for fiscal year 2025
Worldwide sales, full year 2026
$66.3 billion to $67.3 billion
Merck Announces Second-Quarter 2026 Financial Results
Adjusted (non-GAAP) earnings per share, full year 2026
$2.66 to $2.76, including a $2.43 per share charge for buying Terns
Merck Announces Second-Quarter 2026 Financial Results
Potential yearly sales from new growth products, by the mid-2030s
More than $70 billion (management's estimate, not adjusted for the chance that some products fail)
Merck Q4 2025 Earnings Presentation
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 5% more than a year earlier. The year before, quarters averaged 5%.

Since Sep 2026 the share price has fallen 5%, from $152.34 to $144.46.

Bull $170.21Base $114.37Bear $68.64Sep 4Nov 16 · $144.46
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start September 4, 2026.

Recently

Coming up

  • Launch under way after July 16, 2026 approval

    Launch of cholesterol pill Lipfendra

    The FDA approved Lipfendra (enlicitide) in July 2026 as the first daily pill of its kind for lowering LDL ('bad') cholesterol. Under Merck's deal with the US government, it will also be offered through a direct-to-patient program.

    Merck's LIPFENDRA (enlicitide) approved by the U.S. FDA (company press release)
  • January 1, 2027

    Medicare set price for Janumet takes effect

    A government-set Medicare price for Janumet and Janumet XR starts on January 1, 2027. Januvia's set price started on January 1, 2026.

    Merck & Co., Inc. Form 10-K for fiscal year 2025
  • 2027 (price effective 2029)

    Keytruda expected to be chosen for Medicare price setting

    Merck expects the US government to pick Keytruda for price setting in 2027, with the set price starting January 1, 2029.

    Merck & Co., Inc. Form 10-K for fiscal year 2025
  • December 2028

    Possible start of US Keytruda copycat competition

    Keytruda's main US compound patent expires in December 2028. Merck expects lawsuits over two related patents that run to 2029, and expects copycat versions to hurt Keytruda sales materially between 2028 and 2029.

    Merck & Co., Inc. Form 10-K for fiscal year 2025

Our own estimate moved too: the base case went from $48.56 to $114.37 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Heavy reliance on Keytruda

    Keytruda was 49% of sales in 2025. Merck expects copycat versions in the US as early as December 2028 and in Europe around 2031, which would cut its sales.

    From the company's own filingsWould hit how fast sales growMerck & Co., Inc. Form 10-K for fiscal year 2025

  2. US government price setting

    Under the Inflation Reduction Act, Medicare prices are being set for Januvia, Janumet and Lenvima. Merck expects Keytruda to be chosen in 2027, with a set price from 2029, and expects its US Keytruda sales to fall significantly after that.

    From the company's own filingsWould hit how fast sales growMerck & Co., Inc. Form 10-K for fiscal year 2025

  3. Patents running out on older medicines in 2026

    Januvia and Janumet lose US patent protection in May 2026 and Bridion in July 2026. Merck expects to lose nearly all US sales of the diabetes drugs and to stop selling Bridion in the US by the end of 2026.

    From the company's own filingsWould hit how fast sales growMerck & Co., Inc. Form 10-K for fiscal year 2025

  4. Lower prices from government deals and payers

    Merck's 2025 agreement with the US government means discounts for Medicaid and prices tied to other countries for many new launches. Insurers, Europe, Japan and China are also pushing prices down, which can shrink profit margins.

    From the company's own filingsWould hit how much of each sale it keepsMerck & Co., Inc. Form 10-K for fiscal year 2025

  5. Weak vaccine sales in China

    Gardasil sales in China fell sharply in 2025, which made Merck's whole China business shrink significantly. Merck does not expect them to rise meaningfully in 2026.

    From the company's own filingsWould hit how fast sales growMerck & Co., Inc. Form 10-K for fiscal year 2025

  6. New drugs may not replace lost sales

    Most experimental drugs fail, and one can take more than ten years to reach the market. Merck spends heavily on research and acquisitions, and that spending may not produce products big enough to make up for sales lost to patent expiry.

    From the company's own filingsWould hit how much it has to reinvestMerck & Co., Inc. Form 10-K for fiscal year 2025

  7. China Gardasil shipments declined steeply in 2025, proving that diversification products can encounter abrupt regional demand disruptions.

    From our researchWould hit how fast sales growMerck Form 10-K Filing

Is it a good business?

From 2009 to 2025 it earned between 1% and 38% on its shareholders' equity, a median of 30%.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on equity35%
20092025
Return on invested capital is operating profit after tax (at the median effective rate, 14%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares has held roughly steady over the past year.

It owes $44.1B more than it holds in cash. An operating-profit comparison is unavailable from the published quarters.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $144.46. Our put its value between $68.64 and $170.21, with $114.37 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $68.64

This scenario assumes that upcoming patent expirations for the company's leading cancer treatment lead to sharp revenue declines and lower profitability that newer medicines cannot fully offset.

Base case, $114.37

This scenario assumes that new cardiovascular treatments and new formulations of existing drugs absorb the impact of patent expirations, allowing sales to rebound after a brief two-year lull.

Bull case, $170.21

This scenario assumes that rapid patient uptake of new injection methods and successful launches of next-generation cancer and heart medications fully overcome patent losses and drive accelerated sales.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects more than we do.Price above value: 26%

For Merck & to be worth today's $144.46, sales would need to grow about 5.7% a year. We assume 1.1%. Over the last 5 years, sales grew 7.9% a year.

−2%0%+2%+4%+6%+8%+10%We assume 1.1%Price needs 5.7%Past 5 yrs 7.9%

Or, if sales grow 1.1% as we assume, the price works with a profit margin of 38.1% (we assume 31.0%).

Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.

Do you think sales can grow 5.7% a year?

Try your own numbers

We're moderately sure of this range: it scores 60 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $114.37 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average1.1%
  • Operating margin31.0%
  • Long-term growth rate2.3%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$114.37 -20.8%

Build